Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

First-in-Class Hit Finding, The In-Silico Way – Webinar by Jubilant Biosys

Author: Phil Stephan
by Phil Stephan
Posted: Feb 12, 2021
jubilant biosys

Webinar Date:

Thursday, 25th February 2021

Webinar Description:

A showcase of our computational chemistry capabilities with emphasis on virtual screening and scaffold-hopping campaigns for first-in-class targets demonstrated through scientific case studies. Application of latest Machine Learning algorithms to various end-points.

Insights into Jubilant Biosys’ current Machine Learning model development, as a platform, for CardioTox, including individual classification models for hERG, Nav1.5 and Cav1.2, and many more similar models through the value chain.


Rajendra Kristam

Principal Scientist, Computational Chemistry

Rajendra has more than 17 years’ experience in Traditional and Computational Chemistry, beginning his career with Eli Lilly Research Centre, Windlesham, UK.

Before joining Jubilant Biosys, he worked with Aurigene Discovery Technologies and has been associated with Biosys for the last 14 years. Rajendra holds MSc. Chemistry from University of Hyderabad and MSc. Chemoinformatics from University of Sheffield, Sheffield, UK. He is an MBA (Marketing) from Osmania University, Hyderabad, with many research articles and patents to his credit.

Rajendra heads the computational chemistry function at Jubilant Biosys and leads his team to support drug discovery projects. He has guided many virtual screening campaigns and scaffold-hopping efforts for hit-identification. He has been part of teams that delivered five clinical candidates and other targets too.

Saurabh Kapure

Vice President – Business Development (US & APAC)

Saurabh has over 18 years of experience in corporate and international business development in pharmaceutical and drug discovery contract research organizations, marketing (product/brand management), strategic planning, alliance and process management.

He has worked across various geographies like Europe, North America and Asia wherein he created and built businesses from scratch. His experience is spread across multiple Indian pharma cos including Torrent Pharma, Piramal Enterprises and Dr. Reddy’s Laboratories where he worked in various businesses around branded generics and Drug Discovery service providers including Aurigene Discovery, AMRI Global and Panacea Biotech both in managerial and leadership roles.

About Jubilant Biosys Limited:

Jubilant Biosys is a leading contract research organization that offers contract research & development services for global pharmaceutical innovators. Biosys has demonstrated expertise in functional services such as Biology, DMPK, Toxicology as well as Medicinal Chemistry, PR&D and GMP scale-up capabilities up to phase II. It has a proven track record of delivering over 75 integrated programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases.

Jubilant Biosys at a Glance:

    • A boutique CRO with a talented team of 700+ scientists
    • New and adaptable technologies to accelerate drug discovery and improve decision-making quality
    • A highly experienced scientific team that has delivered 75+ integrated discovery programs
    • Continuous investment in the future of drug discovery and development through expansion
    • Leadership with a global presence in the US, EU, and Japan

Jubilant Biosys Limited (JBL)

Bengaluru Research Site:

#96, Industrial Suburb 2nd Stage,

Yeshwantpur Bangalore - 560 022

Karnataka India.

Tel: +91-8066628400

For more info or registration, please visit:

About the Author

I'm a digital marketing enthusiast that specializes in strategy and growth in the digital world, currently working with Dignitas Digital, a leading digital marketing agency in Delhi, India.

Rate this Article
Leave a Comment
Author Thumbnail
I Agree:
Author: Phil Stephan

Phil Stephan

Member since: Oct 06, 2020
Published articles: 6

Related Articles